Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Single Intravenous Dose, Ascending Dose Level Study of the Safety, Tolerability and Pharmacokinetics of GLYX-13 in Normal Healthy Volunteers
Brief Summary: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of a single IV dose of GLYX-13, an N-Methyl-D-aspartate (NMDA) receptor glycine site functional partial agonist, in normal, healthy human volunteers.


Options:
A: Arm Label: Esketamine 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 14 mg, Drug: Esketamine 56 mg, Drug: Placebo | Arm Label: Esketamine 28 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 28 mg, Drug: Esketamine 56 mg, Drug: Placebo | Arm Label: Esketamine 56 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 56 mg, Drug: Placebo | Arm Label: Esketamine 84 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 56 mg, Drug: Esketamine 84 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Esketamine 14 mg, Drug: Esketamine 28 mg, Drug: Esketamine 56 mg, Drug: Esketamine 84 mg, Drug: Placebo | Intervention Type: DRUG; Name: Esketamine 14 mg; Assigned to Arm(s): Esketamine 14 mg, Placebo | Intervention Type: DRUG; Name: Esketamine 28 mg; Assigned to Arm(s): Esketamine 28 mg, Placebo | Intervention Type: DRUG; Name: Esketamine 56 mg; Assigned to Arm(s): Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo | Intervention Type: DRUG; Name: Esketamine 84 mg; Assigned to Arm(s): Esketamine 84 mg, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo
B: Arm Label: IV normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV normal saline | Arm Label: IV GLYX-13; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: SC GLYX-13; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Intervention Type: DRUG; Name: GLYX-13; Assigned to Arm(s): IV GLYX-13, SC GLYX-13 | Intervention Type: DRUG; Name: IV normal saline; Assigned to Arm(s): IV normal saline
C: Arm Label: Part 1: Block A MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block B MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block B Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block C MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block C Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block D MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block D Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 2: MK-8777 200 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 2: MK-8777 800 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: MK-8777; Assigned to Arm(s): Part 1: Block A MK-8777, Part 1: Block B MK-8777, Part 1: Block C MK-8777, Part 1: Block D MK-8777, Part 2: MK-8777 200 mg, Part 2: MK-8777 800 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Block A Placebo, Part 1: Block B Placebo, Part 1: Block C Placebo, Part 1: Block D Placebo, Part 2: Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: B